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The engineering, characterization, and application of dual-functional delivery vehicle “SPIONs–Br–FA” are
reported. In this study, a citrate-coated SPIONs (superparamagnetic iron oxide nanoparticles) drug-delivery
vehicle was conjugated with Br (bromelain), a phytotherapeutic anticancer agent, and ﬁnally immobilized
with FA (folic acid), as a targeting moiety to the FAR+, folate receptor positive, cancer cells. Then, in vitro
compatibility tests were performed to conﬁrm the biocompatibility of the engineered system. A
cytotoxicity study was carried out, which showed a signiﬁcant dose advantage with SPIONs–Br–FA in
reducing the IC50 values of FAR+ cancer cells compared with neat Br. Through morphological
alternation studies, it was disclosed that the SPIONs–Br–FA-treated cells had undergone apoptosis,
since shrinkage as well as apoptotic bodies were obviously observed. We demonstrated that SPIONs–
Br–FA was a good candidate to suppress the migration of the FAR+ cancer cells as well as to inhibit
colony formation of the FAR+ cancer cells compared to SPIONs–Br. We found that the apoptosis
percentage was sharply increased in the FAR+ cancer cells treated by SPIONs–Br–FA compared to those
treated by neat Br. Moreover, the qualitative and quantitative biodistribution study performed on the vital
organs and tumor indicated a signiﬁcant tumor targetability of the SPIONs–FA. Next, we demonstrated
the administration of SPIONs–Br–FA through the tail vein could reduce the tumor burden in 4T1-bearing
mice and also increased their lifespan when compared with SPIONs–Br and neat Br at the same
concentration of bromelain. In conclusion, the results indicated that the synthesized SPIONs–Br–FA is
a promising tool in the ﬁeld of biomedicine, particularly in cancer therapy.1. Introduction
Cancer remains a major health problem and involves various
genetic and cellular abnormalities.1,2 In the past decade, it has
received much attention from researchers3–6 as the mortality
rate due to cancer continues to rise.7 Despite several advance-
ments in conventional treatment, such as surgery, chemo and
radiation therapy, the progress of research in this area still
requires new initiatives. Recent advances in drug delivery havetment of Bioprocess Engineering, Faculty
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ad, Iran
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rsiti Teknologi Malaysia, Skudai 81110,
tion (ESI) available. See DOI:
94greatly improved the pharmacokinetics and dynamics of the
drugs in addressing some of the issues the current drugs have
with poor bioavailability, stability and high systemic toxicity.8–10
In spite of these advances, immune clearance as well as
diﬃculties in achieving eﬀective concentration and targeted
selectivity remain challenging and demanding.11–13 The last few
years have witnessed the development of a number of
nanoparticles-based therapeutic agents for various diseases as
these oﬀer several advantages, such as longer circulation time,
enhanced permeability and retention (EPR), and improved
bioavailability of drugs.14,15 Some studies carried out recently
showed that SPIONs are rewarding magnetic nanoparticles
possessing superb characteristics; for instance, recent studies
have shown that RBCmembrane-coated SPIONs could resist the
immune response as well as have rapid clearance in the body,
which is known as a major challenge in nanomedicine.16,17
In the current era, it is essential and also crucial to develop
sensitive, specic, and accelerated methods for the diagnosis
and therapy of cancer since it is a serious concern in the
international community and the current treatments utilized
are insuﬃcient.18,19 Recent advances in nanotechnology haveThis journal is © The Royal Society of Chemistry 2017
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View Article Onlineintroduced ultrasmall platforms, such as superparamagnetic
iron oxide nanoparticles (SPIONs), which invaluably oﬀer an
improvement in cancer therapy, such as targeted drug
delivery,20 magnetic tumor-targeting hyperthermia,21 various
localized therapies,22 cell labeling,23 cell tracking,24 magnetic
resonance imaging,25–27 and photothermal therapy.28 Cengelli
et al.29 coated uorescent SPIONs with PEG and then immobi-
lized a uorescent reporter molecule, and then administered
the system to a microglial cell culture containing nervous
system immune cells, where the results obtained proved that
the engineered SPIONs possessed satisfying biocompatibility as
well as remarkable intracellular uptake. In another study,30
magnetite nanoparticles were loaded with doxorubicin and
then conjugation of an antibody to the drug was carried out,
and the combination made was then used for simultaneous
cancer diagnosis and therapy. The results showed the sustain-
able release of encapsulated doxorubicin with no inhibition due
to presence of the magnetic nanocapsules. Kubo et al.31 per-
formed implantation of permanent magnets in the sites of
hamster solid osteosarcoma and carried out the delivery of
cytotoxic compounds through magnetic liposomes, whereby
cytotoxic drug delivery was increased by a factor of four times in
comparison with conventional intravenous (nonmagnetic)
delivery.31 Moreover, a remarkable increase in anti-tumor
activity was seen and weight-loss as a side eﬀect was elimi-
nated.32 In 2011, Yoo et al.33 used folic acid and cy5.5 to func-
tionalize SPIONs in order for them to be used in the lung-
cancer-targeted optical imaging of lung cancer, where
stronger optical imaging was observed in the lung cancer
model. In 2011, another study showed good intracellular drug
distribution and interaction for doxorubicin-SPIONs on MCF-7
cells in comparison with a solution of neat doxorubicin.34
Recently, Nasiri et al.35 showed that the cytotoxic eﬀect was
improved in papain-conjugated cobalt ferrite nanoparticles
compared to neat papain. Similarly, Mosafa et al.36 demon-
strated the identical characteristics of papain-immobilized
magnetic nanoparticles compared with neat papain.
Nowadays, SPIONs have been preclinically studied and studies
are now beginning with clinical trials.25,37 Various routes are
available for SPIONs synthesis, such as sono-chemical synthesis,
emulsion, thermal decomposition, co-precipitation, and hydro-
thermal synthesis.38,39 Co-precipitation is known as a simple and
reliable method to synthesize SPIONs with diameters <20 nm.40
SPIONs have been lately found to be highly potent to perform as
a drug-delivery vehicles, since they are poorly toxic41 and possess
a suﬃcient amount ofmagnetic saturation.42Our previous study43
showed that the conjugation of folic acid (FA) to citrate-coated
SPIONs could enable the fabrication of a novel complex pos-
sessing the ability to target the FAR+ cancer cells43–47 while pos-
sessing remarkably biocompatibility.43
In recent years, a variety of naturally occurring dietary
compounds have been shown to possess signicant anticancer
properties.48 Among these, bromelain (EC 3.4.22.33), a cysteine
proteinase derived from pineapple (Ananas comosus), has been
used for several therapeutic applications, such as the inhibition
of platelet aggregation, as an anti-inammatory agent, in
modulation of cytokines, in enhancing the absorption ofThis journal is © The Royal Society of Chemistry 2017antibiotics, and as an anti-tumor activity agent.49–51 Bromelain
(Br) is known as an eﬀective anticancer phyto-therapeutic agent.
The acceptance of Br as a phyto-therapeutical drug among
researchers is now increasing because of its higher eﬃcacy and
non-toxic nature.52 Also, it was found that the beginning of
tumorigenesis was delayed while the number of tumors were
reduced due to pre-treatment with Br in a mouse skin cancer
model.49 In Central and South America, pineapple has been
known as a folk medicine for centuries. The plant's medicinal
properties are related to bromelain, which is an extract from the
stem of the pineapple that has been marketed for the last six
decades.51 Bromelain's multiple constituents are the reason why
it is medicinally benecial; for instance, Br contains proteolytic
enzymes comprising sulydryl53 as well as peroxidase, eschar-
ase (a nonproteolytic component with debriding eﬀects),
glucosidases, acid phosphatase, several protease inhibitors,
cellulases, carbohydrates, organically bound calcium and
glycoproteins.52,54 Bromelain has proved its capabilities to aﬀect
physiological processes, such as coagulation, inammation,
and the immune response. Hence, through preclinical and
clinical studies, the therapeutic eﬀects of bromelain either
alone or in combination with other therapeutics have been
evaluated, and has indicated some clinical benets.55 It was
revealed that the anticancer activity of bromelain may be due to
the protease components it possesses.56 To apply eﬀectively, it is
necessary to nd a new approach for targeting the delivery of Br,
and also to enhance Br concentration at the tumor site. In the
past few years, the complete release of native protein from orally
delivered carrier systems has become a major problem due to
a high probability of protein degradation and instability.
Proteins are therapeutically inactive while aggregated or dena-
tured and can cause unforeseeable side eﬀects, including
toxicity and immunogenicity. Our previously published study43
showed that bromelain possesses remarkable anticancer eﬀects
on ovarian and colon cancer cell lines, but it had toxic eﬀects
toward normal cell lines. So, synthesizing a safe targetable
delivery system to minimize the side eﬀects of bromelain on
normal cell lines and to maximize their toxic eﬀect on tumor
site is highly required.
In this study, the synthesis, characterization, and evaluation
of dual-functional nanocarrier (SPIONs–Br–FA) for the delivery
of anticancer agents, namely bromelain, was investigated.
Nobody has tried the nano-delivery of bromelain using g-Fe2O3
to the FAR+ cancer cells before this, but, in this study, Br was
conjugated to the citrate SPIONs and nally it was targeted to
the FAR+ cancer cells using FA resulting in the synthesis of
a novel biocompatible dual-functional therapeutic biomaterial
with desired characteristics. The anti-tumor eﬃcacy of the
formulated SPIONs–Br–FA in diﬀerent cancer cell lines was
measured and in vivo studies were user to evaluate the eﬃcacy
in the 4T1-bearing Balb/C mice model.
2. Materials and methods
Materials
The chemicals utilized in the current research were all analyti-
cally pure, including sulfuric acid (H2SO4) (QRe¨C), iron(II)RSC Adv., 2017, 7, 40074–40094 | 40075
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View Article Onlinechloride (FeCl2) (99% purity, Sigma Aldrich), iron(III) chloride
(FeCl3) (45% purity, Riedel-de Haen), acetone (QRe¨C), hydro-
chloric acid (HCl) (37% purity, QRe¨C), folic acid (Sigma
Aldrich), potassium bromide (KBr, Sigma Aldrich), N-ethyl-N-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC, 99%
purity, Sigma Aldrich), N-hydroxy succinimide (NHS, 98%
purity, Sigma Aldrich), bovine serum albumin (BSA, Sigma
Aldrich), Bradford Reagent (Sigma Aldrich), bromelain (Merck),
HSF 1184 cell line (human skin broblast cell line, ATCC
Manassas, VA), HeLa cell line (human cervical cancer cell, ATCC
Manassas, VA), MDA-MB-468 cell line (human breast cancer
cell, ATCC Manassas, VA), MDA-MB-231 cell line (human breast
cancer cell, ATCC Manassas, VA), 4T1 cell line (animal stage IV
human breast cancer cell, ATCC Manassas, VA), fetal bovine
serum (Gibco, USA), trypsin EDTA (Gibco, USA), phosphate
buﬀered saline (PBS, Gibco, USA), MES sodium salt (MES,
Sigma Aldrich), Dulbecco's modied eagle's medium (DMEM,
Gibco, USA), RPMI medium 1640 (Gibco, USA), penicillin–
streptomycin (Gibco, USA), dimethyl sulfoxide (DMSO, Sigma
Aldrich), thiazolyl blue tetrazolium bromide (MTT, Sigma
Aldrich), Prussian blue test kit (Sigma Aldrich), cisplatin (Sigma
Aldrich), paraformaldehyde (Sigma Aldrich), and osmium
tetroxide solution (Sigma Aldrich). In all the experiments, water
was previously deionized (18 MU). Moreover, 5 week-old female
Balb/C mice and all their requirements were procured from
Bistari Co., Malaysia.
Preparation of the activated SPIONs–COOH core material
Maghemite nanoparticles were fabricated through a co-
precipitation method described in our previous study.43 In
brief, a solution of ferric chloride and ferrous chloride was
mixed with ammonium hydroxide. The resultant magnetites
were magnetically separated and washed via deionized water.
The excess base was then removed using a solution of nitric acid
in order to accomplish the neutralization of the precipitate.
Then, oxidization of the obtained magnetites to maghemites
was performed by adding ferric nitrate at 100 C for 0.5 h.
Subsequently, washing of the precipitate with acetone was
carried out prior to the product being nally dispersed in water
to obtain stable g-Fe2O3 (pH ¼ 7). Aer the maghemite
synthesis, 50 ml of ferrouid sample was added to 5 g of CA
dissolved in 10 ml DI-water initially and the temperature was
raised to 90 C under continuous stirring for 90 min. The
mixture was cooled down to room temperature until blackish
precipitates were observed. The procedure was continued by
washing using acetone to acquire citric acid-coated SPIONs
(SPIONs–COOH).43,57 The nal product was named SPIONs–
COOH.
Bromelain conjugation
Conjugation of the bromelain to the coated SPIONs was per-
formed through the EDC/NHS click chemistry reaction.58–60 In
brief, a mixture of N-ethyl-N-(3-dimethylaminopropyl)carbodii-
mide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) in
MES buﬀer (0.05 M, pH ¼ 5.7) was added to 5 ml of activated
SPIONs–COOH and mixed at ambient temperature for 1.5 h.40076 | RSC Adv., 2017, 7, 40074–40094Then, the resulting solution underwent a careful two-fold
washing via phosphate buﬀer solution (PBS), pH ¼ 7.4, and
removal of the aqueous layer was carried out aerwards.
Bromelain (27 mg ml1, in 5 ml PBS, pH ¼ 7.4) was then mixed
with the activated SPIONs–COOH and the mixture was stirred
for the next 3 h. Then, the reaction was quenched through the
addition of 25 mM glycine in PBS for 0.5 h with continuous
stirring. Washing was performed three times using PBS, until
nally the suspension of the nal product (SPIONs–Br) was
ready for further use.
Determination of the amount of conjugated bromelain
The amount of bromelain conjugated onto the nanoparticles
was determined by measuring the initial and nal concentra-
tions of bromelain using the Bradford method, in which Coo-
massie protein assay reagent was used while BSA was used as
the standard.61
Folic acid conjugation and loading content determination
Folic acid (FA) was conjugated to the SPIONs–Br and then the FA
loading content was determined using the same method as
described in Nasiri et al.43 The nal resulting nanocarriers were
called SPIONs–Br–FA.
Characterization
The size of the obtained samples was evaluated using trans-
mission electron microscopy (TEM) (Hitachi H-7500), where
analysis of the snapshots assisted approximating the nano-
particles' diameters. Field emission scanning electron micros-
copy (FESEM, JSM-6700F, JEOL, Tokyo, Japan) was carried out to
evaluate the morphology of the samples. The accelerating
voltage was 5 kV, while the working distance between the
detector and the samples was 1.5 cm. Subsequently, the snap-
shots obtained were transformed to 3D images using NIH
Image J soware (1.46r/Java 1.6.0_20 (32 bit)).
The chemical integrity was investigated aerward using
Fourier Transform Infrared Spectroscopy (FT-IR) spectra anal-
ysis in the range of 400–4000 cm1.
The hydrodynamic diameters and surface zeta potential were
gauged using a Nano Zetasizer particle-sizing instrument
(Malvern Instruments, Malvern, UK) aer the nanoparticles
powder was diluted in deionized distilled water. Equilibration
of the samples was performed at 25 C for 5 min prior to each
measurement.
Atomic absorption spectroscopy (SpectrAA-10 Plus spec-
trometer, Varian, France) at 248.3 nmwas used to determine the
iron concentration in the samples.
The changes in the chemical and physical characteristics of
the samples were measured using thermogravimetric analysis
(TGA) via a thermogravimetric analyzer (Shimadzu, model TG-
50) under certain adjustments: heating rate of 10 C min1,
N2 owing rate of 50 ml min
1, and temperature ranging from
25 C to 800 C.
Verication of the crystalline structures was performed via X-
ray diﬀraction using a Panalytical X'PERT MPD X-ray diﬀrac-
tometer. The diﬀractometer was equipped with a copper anodeThis journal is © The Royal Society of Chemistry 2017
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View Article Onlinethat could generate high intensity Cu Ka radiation (l ¼ 1.54065
A˚). The range of 2q was between 10 and 90.
Anti-coagulation assay
A semi-automated blood coagulation analyzer Clot SP was
employed to determine the pro-thrombin time (PT), thrombin
time (TT), and the activated partial thromboplastin time (APTT)
of human blood incubated with samples for intrinsic, extrinsic,
and both intrinsic and extrinsic pathways, respectively. The
brinogen formation time (FB) of the samples was also
measured using the same device. The blood sample was ob-
tained from a male donor (29 years old, no history of extreme
disease) at the Health Centre of Universiti Teknologi Malaysia
(UTM) and transferred to the tube containing citrate to avoid
the blood sample from coagulating. Informed consent was ob-
tained from the donor for the use of their blood and the
dissemination of information about their blood in the scientic
record. The procedure was accepted as satisfactory by the
Medical Advisory Committee and the Clinical Ethics Committee
of Sultanah Aminah Healthcare Hospital Berhad, Malaysia, in
association with the Ministry of Health (MOH). PBS solution
(pH ¼ 7.4) was used to dilute the samples (0.2 ml) and the
diluted samples were incubated together with 500 ml plasma of
fresh human blood under specic conditions: 30 min, 37 C,
and in a transparent plastic tube. Eventually, the PT, TT, APTT,
and FB were measured three times for each of the samples.62 In
order to carry out the hemolysis study, 100 ml of washed RBCs
together with 900 ml of each of the samples dispersed in saline
was incubated for 2 h, followed by centrifugation for 5 min at
1500 rpm. Subsequently, to the collected supernatant, 900 ml of
saline was added and via a UV spectrophotometer (Carywin UV),
the absorbance was recorded at 541 nm. The coagulation test in
a slide method was carried out to determine the hard clot
formation time on slide. The synthesized samples were diluted
in 0.2 ml of phosphate buﬀered saline (PBS) solution (pH¼ 7.4).
The samples were incubated with a drop of blood on the glass
slide at 37 C. Every 30 s, the needle was placed in the middle of
a blood drop and it was then elevated. Blood coagulation started
when brin threads appeared attached to the needles. Through
manually dipping a silicon-coated stainless steel hook into the
solution, hard clot formation was closely monitored via the
detection of brin threads. Clotting time was recorded once the
rst brin formation sign was seen, and the clotting time was
recorded. In order to obtain reliable values, each test was
repeated three times (with hard clot formation normally taking
place in 5 to 10 min).
Cell lines
The HSF 1184 (normal human skin cell line), HeLa (human
ovarian cancer cell line, FAR+), MDA-MB-468 (human breast
cancer cell line, FAR), MDA-MB-231 (human breast cancer cell
line, FAR+), and 4T1 (animal stage IV breast cancer cell line,
FAR+) cell lines were purchased from ATCC. The HSF 1184,
MDA-MB-231 and MDA-MB-468 cell lines were both cultured in
DMEM medium supplemented with 10% fetal bovine serum
(VWR, Visalia, CA) and 1% penicillin–streptomycin (Sigma, St.This journal is © The Royal Society of Chemistry 2017Louis, MO). HeLa and 4T1 cell lines were cultured in RPMI 1640
medium with 10% fetal bovine serum (VWR, Visalia, CA) and
1% penicillin–streptomycin (Sigma, St. Louis, MO). Cells were
maintained at 37  0.5 C in a humid atmosphere of 5% CO2 (v/
v) in air. All the tests were accomplished when the cells were in
their exponential growth phase.
Anti-proliferation assay
Tetrazolium dye (MTT) assay was carried out for evaluation of
the viability of HSF 1184, HeLa, MDA-MB-468, MDA-MB-231,
and 4T1 cell lines when they are treated with bare SPIONs,
SPIONs–COOH, SPIONs–FA, neat Br, SPIONs–Br, and SPIONs–
Br–FA.63 Aer being harvested, the cells were resuspended in
their related medium at 5  104 cells/200 ml. Subsequently, 24-
well plates were used to culture the cells. Aer 24 h, the medium
of each cell line was removed and replaced with 200 ml of each
sample (100, 200, 300, 500, 1000 mg ml1) diluted with medium
and located in an incubator for 24 h. Then, 20 ml of MTT (5 mg
ml1) was added prior to 4 h incubation in absolute darkness
since this reaction is highly sensitive to light. Subsequently, the
formulations were aspirated prior to the addition of 200 ml of
DMSO in order for formazan crystals to be dissolved. Aer-
wards, measurement of the absorbance at 570 nm was carried
out via a microplane reader (BioRad). The medium was used as
blank while untreated cells were used as the control with 100%
viability. Finally, the results are expressed herein as mean
values  standard deviation of 6 independent measurements.
Compared to the control group, the relative cell viability (%) was
calculated via eqn (1).
Cell viability ð%Þ ¼ OD 570 ðsampleÞ
OD 570 ðcontrolÞ  100 (1)
Morphological assessment by phase-contrast inverted
microscopy
The morphological apoptosis of cells aer treatment with neat
Br and SPIONs–Br–FA was observed using an inverted micro-
scope according to the standard protocol.64 A solution of 1 105
cells per ml was seeded in 6-well plates and the cells were
treated for 24 h with neat Br (at the IC50 value) and SPIONs–Br–
FA (at the IC50 value of neat Br), with a 70% level of conuence
achieved. The negative control was the untreated cells, while
cisplatin was used as the positive apoptosis control. Next,
removal of the medium and washing with PBS were carried out
so as to track the morphological alterations occurring.
Apoptosis detection by AO/EB staining
Slight modications were made to Acridine orange (AO) and
ethidium bromide (EB) double staining as described by Gani
et al.65 The cells were treated with neat Br (at the IC50 value) and
SPIONs–Br–FA (at the IC50 value of neat Br) for 24 h. Aer 24 h
treatment, using 100 ml of 1 working solution, the cells were
stained. 1 working solution was prepared by mixing 500 mg EB
and 100 mg AO in 1 ml of PBS. Once the cells had undergone
a 10 min incubation, the cells were observed using a uorescentRSC Adv., 2017, 7, 40074–40094 | 40077
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View Article Onlinemicroscope (Olympus). The nuclei of the living cells were
stained green once with AO, which was used as a cell-permeant
dye. Unlike the AO, in cells with ruptured plasmamembranes or
dead cells, the nuclei were stained orange through EB staining.
As a result, live cells with an organized structure were observed
in green, while the dead cells with round nuclei were observed
in orange. From at least 200 cells, the number of viable,
apoptotic, and necrotic cells were counted. The percentages of
apoptotic and necrotic cells were then calculated using eqn (2)
and (3), respectively,
Acellð%Þ ¼ Na
Nt
 100 (2)
Ncellð%Þ ¼ Nn
Nt
 100 (3)
where Acell (%) stands for the percentage of apoptotic cells, Ncell
(%) stands for the percentage of necrotic cells, Na is the number
of apoptotic cells, Nn represents the number of necrotic cells,
and Nt is the total number of cells.Scratch motility assay
In order to measure the ability of the FAR+ cells treated with
neat Br (at the IC50 value) and SPIONs–Br–FA (at the IC50 value
of neat Br), a scratch assay was performed according to Amini
et al.,64 with slight modications. Briey, in a 6-well plate, 3 
105 cells per well were seeded and incubated to obtain
a conuentmonolayer. Using a cell scrapper, themonolayer was
linearly scratched and the debris and the detached cells were
removed aer being gently washed via PBS. Next, treatment of
the cells via neat Br and SPIONs–Br–FA was performed. The
negative control wells were lled using the complete medium
and incubated at 37 C, while the migrated distance by the cells
was measured at 0, 12, and 24 h using an inverted phase-
contrast microscope (Zeiss Axiovert 100). For evaluation and
comparison of the width of the scratches at each time interval,
NIH Image J soware was operated. Statistical calculations were
performed to obtain the healing rates, while the nal results
were released as cell migration percentages.Clonogenic inhibition assay
Previously, a clonogenic cell survival assay was performed as
described by Gani et al.,65 with slight modications. In brief,
cells in their growth log phase were trypsinized. Then, a tripli-
cate seeding of almost 1 103 cells per ml into 6-well plates was
performed and the medium was replaced by a medium con-
taining neat Br (at the IC50 value) and SPIONs–Br–FA (at the IC50
value of neat Br) a day later. A day later, fresh medium replaced
the extracts and the cells were maintained at 37 C in a CO2
incubator for 10 days, during which growth media were
refreshed every 2 days. Fixation of the colonies was carried out
using 20 C methanol and staining with 0.5% trypan blue
solution. The results were then expressed as q colony-forming-
potential percentage for the colonies including 50 or more
cells. Eqn (4) was used to calculate the eﬃciency of the colony
formation:40078 | RSC Adv., 2017, 7, 40074–40094hc:f ¼
Nc
Ni
 100% (4)
where hc.f is the colony formation eﬃciency, Nc is the number of
the colonies formed, and Ni is the number of cells incubated.In vivo analysis
Animal handling and establishing the 4T1-bearing mice
model. The Institutional Review Board of the Universiti
Kebangsaan Malaysia Animal Ethics Committee (UKMAEC),
Selangor, Malaysia, approved this study and granted its ethical
endorsement (UTM/2014/ANI/26 NOV/625). A submitted full
research proposal, an interview, and hands-on animal training
session were required for the ethical clearance. Data collection
was performed at the Universiti Teknologi Malaysia as the
housing location. Therefore, according to the rules and regu-
lations set by the UKMAEC, proper handling of all the experi-
mental protocols were carried out.
The maintenance of the 15 to 20 g and 6 week-old female
Balb/C mice were carried out using wood shavings-bedded
polypropylene cages at ambient temperature, while the mice
had unlimited access to water and a folate-decient diet over
the course of the experiment in order to decrease the level of
folic acid to the minimum,66 while a 12 h light/dark cycle was
applied. The adaptation period was considered to be 7 days.
Female Balc/C mice were each subcutaneously injected with 1
106 4T1 murine mammary carcinoma cells (n ¼ 6) into the
mammary fat pad for establishment of the mice bearing the
breast cancer tumor. Two to three weeks later, the 4T1-injected
mice with palpable primary tumors were observed.
The standard protocol of H&E staining was followed to
conrm the presence of tumor cells under an inverted micro-
scope (Nikon Eclipse Ti-s examination).67 In brief, tissue
removal was carried out upon necropsy and the removed tissue
underwent xation in formalin (10%). Subsequently, the pro-
cessed tissues were paraﬃn-embedded, sectioned at 5 mm,
located on glass slides, and stained via hematoxylin and eosin
through standard procedures.
Quantitative biodistribution study in the 4T1-bearing mice
model. A quantitative biodistribution study was carried out
according to ref. 68 and 69, with slight modication. The 4T1-
bearing mice were injected via the tail vein with 100 ml of
SPIONs–COOH and SPIONs–FA (10 mg kg1) and sacriced at 4,
12, and 24 h time points. The blood was collected by cardiac
puncture and, aer euthanasia, the heart, liver, spleen, lungs,
kidneys, stomach, muscle, and tumor were collected, weighed,
and dissolved completely by adding 2 ml of HCl and 1 ml of
HNO3 at 70 C for 6 h. The solution was diluted with deionized
water and ltered with a 0.45 mm Teon lter. The sample was
analyzed for iron by atomic absorption spectroscopy (AAS)
(VARIAN, model AA240FS). The uptakes of the nanoparticles in
the organs were calculated as a mean percentage of the injected
doses per gram of organ tissues (% ID per g). Each sample and
time point included six independent repetitions.
Qualitative biodistribution studies in the 4T1-bearing mice
model. Qualitative biodistribution studies in the 4T1-bearing
mice were performed by TEM. The 4T1-bearing mice wereThis journal is © The Royal Society of Chemistry 2017
Table 1 First group in the in vivo study
Group I Saline
Group II SPIONs–COOH 10 mg kg1
Group III Neat Br 10 mg kg1
Group IV SPIONs–Br 4 mg kg1
Group V SPIONs–Br 8 mg kg1
Group VI SPIONs–Br 10 mg kg1
Table 2 Second group in the in vivo study
Group I Saline
Group II SPIONs–FA 8 mg kg1
Group III SPIONs–Br–FA 8 mg kg1
Group IV SPIONs–Br–FA + coinjection
of excess folic acid
8 mg kg1
Group V SPIONs–Br 8 mg kg1
Group VI Neat bromelain
(at the same concentration of Br in
conjugated nanoparticles 1 mg kg1)
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View Article Onlineinjected via the tail vein with 100 ml of SPIONs–FA (10 mg kg1)
and sacriced at 24 h aer injection. To verify the SPIONs–FA
biodistribution in the major organs, including the heart, liver,
spleen, lungs, kidneys, stomach, muscle, and tumor, these tissues
were collected and washed with PBS. These tissues were xed
using paraformaldehyde (10%) and were paraﬃn-embedded.
Using an ultramicrotome, the sections were prepared in an
ultrathin manner. Then, the ultrathin sections were mounted on
200 mesh copper grids stained with 2% osmium tetroxide (dis-
solved in distilled water) for 30 min according to the standard
procedure.70 All the stained sections were observed under a Hita-
chi HT7700 Bio-Medical TEM microscope.
In vivo anticancer eﬃcacy
The anticancer eﬃcacy of SPIONs–Br and SPIONs–Br–FA were
evaluated in the 4T1-bearing mice model compared with neat
Br. Mice were inoculated with 1  106 cells per mouse on day 0,
followed by treatment with neat Br and nanoparticles in
diﬀerent formulations aer 24 h post inoculation of the 4T1
cancer cells. The mice were randomly divided into 6 groups of 6
as shown in Table 1 (note: aer getting the in vivo anticancer
eﬃciency results of the rst group, the second group of 4T1-
bearing mice model were randomly divided into 6 groups of
6, as shown in Table 2). The same procedure was followed for
the second group of study.
The formulations were administered intravenously three
times a week to the 4T1-bearing mice model. Mice of the control
groups were treated with the same volume of normal saline. The
tumor volume was measured every other day in all the groups.
The diameter of each tumor was measured using a digital
caliper. The obtained readings were used in order to calculate
the tumor size through eqn (5), whereby the eﬀect of the
treatment was assessed:
v ¼ 1
2
ab2 (5)This journal is © The Royal Society of Chemistry 2017where v is tumor volume, a is the longest diameter, and b is the
shortest diameter.
Additionally, the survival rate was calculated using eqn (6):
Rsur ¼ Nsur
Nt
(6)
where Rsur is the survival rate, Nsur is the number of surviving
mice, and Nt is the total number of mice.Statistical analysis
The data were analyzed by one or two-factor ANOVAs with
appropriate post-tests as well as multiple t-test analysis using
GraphPad Prism soware (version 6.0). The obtained results are
reported herein as the mean  S.E.M (standard error of the
mean) of at least three independent experiments. Statistically
signicant data were the ones with a p-value < 0.05.3. Results and discussion
Synthesis and characterizations
The major goal of the present study was to synthesize, charac-
terize, and evaluate the biocompatibility, binding, and anti-
cancer eﬃcacy of exquisite SPIONs–Br–FA in vitro and in vivo.
Fig. 1 illustrates a schematic representation of the study design.
Fig. 1(A) shows the functionalization of the dual-functional
SPIONs–Br–FA. Fig. 1(B) illustrates the in vitro targeting eﬃ-
ciency of the folate-conjugated SPIONs, which is signicantly
higher in FAR+ cells (HeLa, MDA-MB-231 and 4T1) compared to
in the FAR cells (HSF 1184 and MDA-MB-468), while Fig. 1(C)
shows the in vivo eﬀectiveness of SPIONs–Br–FA in the inhibi-
tion of cancer growth compared to the SPIONs–Br and neat Br.
The step-by-step synthetic routes for the CA-coated SPIONs and
Br and FA conjugation are shown in Fig. 2. Initially, the
synthesized SPIONs were stabilized via citric acid, as shown in
Fig. 2(A), followed by Br conjugation through the EDC/NHS click
chemistry method, as shown in Fig. 2(B1) and (B2). The reaction
was followed by FA immobilization of the Br-conjugated
SPIONs, as shown in Fig. 2(C) in order to facilitate the target-
ing eﬃciency of Br-conjugated SPIONs to diﬀerent types of
cancers, such as breast, lung, and cervical, in which the over-
expression of the folate receptor is seen.71–74
We previously reported that FA provides a good cancer cell-
specic target in vitro.43 Here, we present the modication of
targetable nanoparticles by the conjugation of Br (anticancer
agent) to the activated SPIONs–COOH, which serves as
a bromelain (Br) delivery vehicle to the FAR+ cancer cells.
Furthermore, the eﬀectiveness of the nal engineered formu-
lation (SPIONs–Br–FA) was investigated with cancer cells (HSF
1184, MDA-MB-468, MDA-MB-231, and HeLa) and the 4T1-
bearing mice model, respectively.
TEM and FESEM observations (Fig. 3) revealed that the
functionalized SPIONs (SPIONs–Br–FA) were spherical and
nearly uniform (Fig. 3(a3) and (c1)), with an average diameter
size of approximately 23–24 nm (Fig. 3(c3)). Moreover, the
morphology undergoes slight alterations aer functionalization
(Fig. 3(b1) and (c1)) and nanoparticles tend to grow as shown inRSC Adv., 2017, 7, 40074–40094 | 40079
Fig. 1 (A) Schematic presentation of the functionalization of dual-functional SPIONs–Br–FA, (B) SPIONs–Br–FA binding to the FA receptors on
the cancer cells, (C) administration of SPIONs with diﬀerent formulations into the 4T1-bearing mice model, leading to the inhibition of cancer
growth.
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View Article Onlinethe size distribution graph (Fig. 3(b3) and (c3)). The 3D images
of the bare nanoparticles and functionalized nanoparticles are
shown in Fig. 3(b2) and (c2). The SPIONs crystalline nature is
presented in the image provided by high resolution trans-
mission electron microscopy (HRTEM, Fig. 3(a1)). A typical
structure of the core–shell (SPIONs–Br–FA) that was slightly
dispersed appeared upon Br and FA conjugation, as shown in
Fig. 3(a3), while a thick layer (12–15 nm) was clearly observed on
the outer shell of the core. The results obtained via HRTEM are
compared herein to the data obtained via fast Fourier transform
(FFT), as seen in (Fig. 3(a1) and (a2)) and could be indexed as the
(311) plane of cubic SPIONs.40080 | RSC Adv., 2017, 7, 40074–40094Additional characterizations and physicochemical analyses
of the synthesized nanoparticles through various methods,
such as FT-IR, TGA, DLS, XRD, and microscopic observations in
the absence of the magnetic eld are reported in the ESI le
(Fig. S1†).Cellular uptake of nanoparticles into 4T1 cancer cells
In our previous published paper,43 the nanoparticles uptake
into HSF 11 84, MDA-MB-231, MDA-MB-468, and HeLa cell lines
was reported. In the current paper, the quantitative uptake
experiments were performed by means of AAS using 4T1 cells,
known to overexpress the folate receptor.75–79 Aer theThis journal is © The Royal Society of Chemistry 2017
Fig. 2 Step-by-step functionalization of dual-functional SPIONs–Br–FA.
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View Article Onlinetreatment of cells with suspensions of SPIONs–COOH and
SPIONs–FA in three diﬀerent concentrations (100, 200, and 300
mgml1) for 4, 12, and 24 h, cells as mineralized cell lysates were
tested to determine their iron content viameasurement of their
atomic absorbance at 248.3 nm. In contrast to SPIONs–COOH,
the uptake of SPIONs–FA by 4T1 cells was about 2-fold higher
(Fig. 4(C)). A binding assay was performed in a competitive
manner for the determination of the dependency of cellular
uptake on the folate receptors in FAR+ cells treated with 1 mMThis journal is © The Royal Society of Chemistry 2017of neat folic acid, which was needed to limit the folate receptor-
dependent binding in a competitive manner. As expected, the
comparative binding assay shows a sharp decreased uptake of
the nanoparticles by the 4T1 cells (Fig. 4(D)). This result indi-
cates that the uptake of SPIONs–FA was mediated by the folate
receptors on the cell surface.43,80,81 On the other hand, the
internalization of SPIONs–COOH and SPIONs–FA were veried
using Prussian blue staining (Fig. 4(A)) and by TEM (Fig. 4(B)).
Fig. 4(A) shows a higher number of nanoparticles, as the blueRSC Adv., 2017, 7, 40074–40094 | 40081
Fig. 3 (a1) TEM and HRTEM images of bare SPIONs, (a2) intensity histogram of SPIONs, (a3) TEM and HRTEM images of the functionalized
nanoparticles, (b1)–(b3) show the FESEM, 3D, and size distribution images of SPIONs, (c1)–(c3) show the FESEM, 3D, and size distribution of the
functionalized nanoparticles.
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View Article Onlinespots, within 4T1 cells in a concentration-dependent manner
aer incubation with SPIONs–FA compared to SPIONs–COOH–
incubated cells. Fig. 4(B) shows SPIONs–FA internalization to
a 4T1 cell by electron microscopy. Although the results obtained
from the TEM and Prussian blue staining conrm the results
obtained from the AAS assay, in which a higher amount of
SPIONs–FA are seen (blue spots) on 4T1 cells when the cells
were treated with SPIONs–FA, a lower number of blue spots was
seen when the cells were treated with SPIONs–COOH. The
results showed that SPIONs–FA was a rewarding option for
targeting 4T1 cancer cells.In vitro biocompatibility evaluation and cytotoxicity assay
The biocompatibility levels of the SPIONs, SPIONs–COOH, and
SPIONs–FA were qualitatively determined using the colori-
metric MTT assay toward HSF 1184, MDA-MB-468, MDA-MB-
231, and HeLa cells as reported in our previous published
paper,43 while the biocompatibility of 4T1 cells were evaluated
in this paper, and for a better comparison, all the data are re-
ported in one graph in this paper. All the HSF 1184, MDA-MB-
231, MDA-MB-468, HeLa, and 4T1 cell lines were incubated
with 100, 200, 300, 500, and 1000 mg Fe ml1 of each SPIONs,
SPIONs–COOH, and SPIONs–FA for 24 h. As illustrated in Fig. 5,
aer 24 h incubation with SPIONs–COOH and SPIONs–FA, the
viability of all the cell types were still >70% at all Fe incubation
concentrations. These results agree with the literature.82,83 The40082 | RSC Adv., 2017, 7, 40074–40094SPIONs–COOH and SPIONs–FA showed <30% cell inhibition,
even at the highest concentration of 1000 mg ml1; however, the
viability of the cells treated with SPIONs was lower in all cases,
showing that while SPIONs are slightly toxic to the cells,
SPIONs–COOH and SPIONs–FA are reliably biocompatible. In
vitro blood compatibility test were carried out and the results
are reported in the ESI le (Fig. S2†), which indicated that the
synthesized delivery system was perfectly tolerable to blood.
In the case of the cells incubated with SPIONs–Br (100, 200,
300, 500, and 1000 mg Fe ml1), SPIONs–Br–FA (100, 200, 300,
500, and 1000 mg Fe ml1) and neat Br (note: the concentration
of neat Br in each group was equal to the concentration of Br in
the corresponding SPIONs–Br and SPIONs–Br–FA groups), the
24 h cell viabilities are also shown in Fig. 5.
The in vitro cytotoxicity proling of SPIONs–Br, SPIONs–Br–
FA, and neat Br in the HSF 1184 and MDA-MB-231, MDA-MB-
468, HeLa, and 4T1 cells are also shown in Fig. 5. The
SPIONs–Br–FA exhibited a boosted cytotoxicity in FAR+ cancer
cells in comparison with cells treated with SPIONs–Br and neat
Br at the same concentrations of bromelain. The IC50 value is
dened as the concentration inhibiting 50% of cell growth, with
a 95% condence interval (95% CI) typically stated at the 95% of
condence level, which measures the probability that a pop-
ulation parameter will fall between two set values. IC50 values of
SPIONs in diﬀerent formulations, neat Br, and cisplatin are
illustrated in Table 3. As shown in Table 3, the IC50 values and
95% CI (condence intervals) of bare SPIONs increased aerThis journal is © The Royal Society of Chemistry 2017
Fig. 4 (A) Prussian blue assay ((a) no treatment, (b) SPIONs–COOH 100 mgml1, (c) SPIONs–COOH 200 mgml1, (d) SPIONs–FA 100 mgml1, (e)
SPIONs–FA 200 mg ml1). (B) TEM image. (C) AAS assay. (D) Competitive binding assay.
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View Article Onlinecitrate coating and remained high even aer folate conjugation,
which shows the low cytotoxicity and compatibility of SPIONs–
FA as a delivery vehicle in contact with the cells.
On the other hand, the calculated IC50 values for SPIONs–Br
were lower for all cells compared to the neat Br. The lower cell
viability (reduced IC50) was assigned to the fact that SPIONs–Br
were eﬃciently endocytotically taken up in comparison with the
molecules of neat Br, which passively nd their way through the
membrane via diﬀusion.84 These results are in agreement with
the results reported by Danhier et al.,85 where it was illustrated
that via the conjugation of doxorubicin (an anthracycline anti-
biotic commonly used in cancer chemotherapy) to nano-
particles, the toxicity was highly increased. The results of this
study suggested that doxorubicin-conjugated nanoparticles
could eﬃciently decrease the eﬀective dose received by patients
over the course of the therapy. Similarly, the toxicity of
oxaliplatin-conjugated nanoparticles was investigated.86 Oxali-
platin is known as a cisplatin analog, which has been utilized
for the treatment of colorectal cancer. However it eﬀectively
works, oxaliplatin does not oﬀer any targeting properties toThis journal is © The Royal Society of Chemistry 2017track and bind to cancer cells, so it attacks any kind of healthy
cells, which uncontrollably divide. To improve this method of
chemotherapy, drug delivery must be enhanced. Brown et al.
showed that the capabilities of oxaliplatin increased when it
was conjugated to nanoparticles. They reported that the in vitro
cytotoxicity aer conjugation was increased by a factor of 5-fold,
which was again assigned to the fact that conjugated particles
could pass the membrane of cancer cells via endocytosis.86
However, in the current study, the IC50 values were signi-
cantly lower for FAR+ cancer cells when treated with SPIONs–
Br–FA compared to when treated with SPIONs–Br and neat Br,
while there was no signicant diﬀerence for FAR cells. It is
evident from the results that the SPIONs–Br–FA was able to
induce signicantly more cell death at low doses (in bold in
Table 3) as compared to neat Br and SPIONs–Br (Fig. 5), espe-
cially for FAR+ cancer cell lines (HeLa, MDA-MB-231, 4T1). The
higher eﬃciency of Br transport via nanoparticles through the
mechanism of the receptor-mediated endocytosis pathway into
FAR+ cancer cells (HeLa, MDA-MB-231, 4T1) in comparison with
themechanism of the passive diﬀusion of neat Br into the FARRSC Adv., 2017, 7, 40074–40094 | 40083
Fig. 5 MTT assay. Each value is the mean  S.E.M. of six replicates out of three independent experiments. (*) indicates a signiﬁcant diﬀerence
compared to the control analyzed by the unpaired t-test, followed by the Holm–Sidak post hoc test (p < 0.05).
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View Article Onlinecancer cells (HSF 1184, MDA-MB-468) may be the reason why
SPIONs–Br–FA exhibited increased cytotoxicity in FAR+ cancer
cell lines.87,88
To conclude, the IC50 value of neat Br had signicant
diﬀerence for the FAR+ cancer cells when compared with
SPIONs–Br–FA, while there were no signicant diﬀerence for
the FAR cell lines. Also, there was no signicant diﬀerence
between the IC50 value of neat Br and SPIONs–Br. Therefore, for40084 | RSC Adv., 2017, 7, 40074–40094further morphological analysis, apoptotic detection, scratch
motility, and the clonogenic inhibition assays, neat Br and
SPIONs–Br–FA-treated cells were compared to each other.Morphological assessment and apoptosis detection
The morphologies of HSF 1184, MDA-MB-468, HeLa, MDA-MB-
231, and 4T1 cells aer treatment with neat Br (at the IC50
concentration), SPIONs–Br–FA (at the IC50 concentration of neatThis journal is © The Royal Society of Chemistry 2017
Table 3 Inhibitory eﬀect (IC50 values) of SPIONs in diﬀerent formulations, neat Br, and cisplatin against cells after 24 h. The IC50 values were
calculated by GraphPad Prism using nonlinear regression analysis
Samples IC50
(mg ml1) (95% CI)
FAR FAR+
HSF 1184 MDA-MB-468 MDA-MB-231 HeLa 4T1
SPIONs 1455 (1047 to 2021) 1188 (941.8 to 1499) 1170 (929.3 to 1473) 1235 (740.7 to 2058) 1144 (719.6 to 1819)
SPIONs–COOH 14 086 (5425 to 36 574) 9273 (2294 to 37 487) 7355 (2918 to 18 540) 7398 (2662 to 20 557) 5088 (5425 to 36 574)
SPIONs–FA 4853 (3071 to 8272) 5185 (2402 to 11 194) 5282 (2777 to 10 050) 5039 (1912 to 13 282) 4726 (3071 to 8272)
Neat Br 240.7 (199.3 to 290.8) 193.1 (177.9 to 209.6) 136.7 (123.1 to 151.7) 100.9 (95.58 to 106.5) 91.55 (85.15 to 98.44)
SPIONs–Br 217.9 (182.8 to 259.7) 195.5 (160.7 to 230.5) 121.6 (112.9 to 131.1) 94.85 (91.03 to 98.84) 88.15 (83.46 to 93.10)
SPIONs–Br–FA 213.3 (184.6 to 246.3) 189.4 (144.6 to 248.1) 101.2 (92.25 to 111) 60.98 (57.32 to 64.88) 61.18 (56.48 to 66.26)
Cisplatin 22.34 (20.75 to 24.05) 16.86 (15.52 to 18.32) 14.34 (13.23 to 15.54) 10.32 (9.526 to 11.18) 9.602 (8.777 to 10.50)
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View Article OnlineBr), and cisplatin (as a positive control, at the cisplatin IC50
concentration) were studied under an inverted microscope are
shown in Fig. 6. A perfect way to depict and dene apoptosis on
the basis of morphological alterations aer treatment is using
phase-contrast microscopy.89 In a previous study by Gani et al.,65
the morphological alternations of colon and ovarian cancerFig. 6 Growth inhibitory eﬀect under an inverted microscope, (a) HS
treatment, (2) neat Br, (3) SPIONs–Br–FA, (4) cisplatin).
This journal is © The Royal Society of Chemistry 2017cells aer Br treatment indicated a bromelain apoptotic eﬀect
on cancer cells. In the current study, the morphological alter-
nations of HSF 1184, MDA-MB-468, HeLa, MDA-MB-231, and
4T1 cell lines aer neat Br and SPIONs–Br–FA treatment were
observed and compared. Apparent changes in morphology were
observed in the treated cells, namely regarding membraneF 1184, (b) MDA-MB-231, (c) HeLa, (d) MDA-MB-468, (e) 4T1 ((1) no
RSC Adv., 2017, 7, 40074–40094 | 40085
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View Article Onlineblebbing (MB), apoptotic bodies (AB), nuclear compaction (NC),
rounded up and oating cells (FC), and cell shrinkage (SH).
These morphological changes were previously reported in
apoptotic cells.89–91 Among themorphological changes and dead
cell characteristics, rounding and cell detachment were more
remarkable in FAR+ cancer cells when treated with SPIONs–Br–
FA compared with neat Br-treated cells. As a result, SPIONs–Br–
FA induced signicant apoptosis compared to neat Br in FAR+
cancer cell lines, which corroborates with the MTT results in
this study.
One key consideration in developing drugs is the apoptosis
induction. Most of the anticancer agents currently in use are
capable of inducing apoptosis in susceptible cells.92,93
Apoptosis: a signicant model of cell death, which is an active
process to destroy the cell, that takes place in response to
diﬀerent agents, such as ionizing radiation or anticancer
agents.94 As a vital dye, Acridine orange (AO) is taken up by both
non-viable and viable cells. The resulting nuclei can be observed
in green under a uorescence microscope, while the cells
stained with ethidium bromide (EB, only non-viable cells) lose
the integrity of their cytoplasmic membrane and their nucleiFig. 7 Detection of apoptosis by AO/EB staining, (a) HSF 1184, (b) MDA-M
(3) SPIONs–Br–FA, (4) cisplatin).
40086 | RSC Adv., 2017, 7, 40074–40094turns red. Based on chromatin condensation, uorescence
emission, and morphological changes, identication of the
diﬀerent types of cells was carried out, where viable cells
showed a normal morphology with uniform green nuclei.
Highly condensed cells, which formed yellow green fragments,
were identied as early apoptotic cells, whereas orange-red
fragmented/condensed nuclei and orange-red chromatin in
round nuclei were a highlighted morphological characteristic of
late apoptotic and necrotic cells, respectively.64 For 24 h, the
cells (HSF 1184 and MDA-MB-231, MDA-MB-468, HeLa, and
4T1) were exposed to neat Br (at the IC50 concentration),
SPIONs–Br–FA (at the IC50 concentration of neat Br), and
cisplatin (as a positive control, at the IC50 concentration of
cisplatin), and then stained with EB and AO. Neat Br-, SPIONs–
Br–FA-, and cisplatin-treated cells exhibited transformed
morphological characteristics of non-viable cells under AO/EB
staining, while green and viable cells with round and non-
aﬀected nuclei were snapped in the negative control groups.
Fig. 7 shows that there were no distinct morphological changes
in the control (i.e., no treatment) groups, but cells exhibited the
induction of apoptosis aer neat Br and SPIONs–Br–FAB-231, (c) HeLa, (d) MDA-MB-468, (e) 4T1 ((1) no treatment, (2) neat Br,
This journal is © The Royal Society of Chemistry 2017
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View Article Onlinetreatments. These results illustrate that SPIONs–Br–FA can
bring about enormous detachment, along with leading to
cluster and aggregate formation of the FAR+ cancer cells
compared with neat Br-treated cells. The frequency of necrotic
cells with uniformly stained orange nuclei and the percentage
of apoptotic cells was sharply increased when FAR+ cancer cells
were treated with SPIONs–Br–FA (Fig. S3†).
Overall, the SPIONs–Br–FA was shown to be more eﬀective at
inducing apoptosis, suppressing the cell growth, and intro-
ducing morphological changes in FAR+ cancer cells compared
to neat Br-treated cells. The reason for this could be the higher
internalization of Br through the FAR receptors on the surface
of FAR+ cancer cells, which causes Br to be more internalized in
the FAR+ cells and establishes a higher cytotoxicity and conse-
quently, changes in the FAR+ cancer cells. These results are in
agreement with the MTT and inverted microscope results.Scratch motility and clonogenic inhibition assays
The cell migration assay was performed on conuent mono-
layers of FAR+ cancer cell lines. Non-treated cells were used as
a negative control. Scratching of the cells was performed, as
explained in the methodology, prior to them being cultured
using fresh medium in the absence or in the presence of neat Br
(at the IC50 concentration) and SPIONs–Br–FA (at the IC50
concentration of neat Br). The data are shown in Fig. 8(a)–(c) forFig. 8 Inhibition of (a) MDA-MB-231, (b) HeLa, and (c) 4T1 cell lines mig
snapped with an inverted phase-contrast microscope (50) at diﬀerent
forming-inhibition potential of neat Br and SPIONs–Br–FA on FAR+ can
This journal is © The Royal Society of Chemistry 2017the HeLa, MDA-MB-231, and 4T1 cell lines, respectively, which
clearly showed that the control cells gained a full conuency
aer 24 h, whereas cells treated with neat Br and SPIONs–Br–FA
showed the ability to migrate to a minimum with a complete
stop in migration 24 h subsequent to the incubation. The ob-
tained results illustrated that the migration of FAR+ cells was
eﬀectively reduced in a time-dependent manner once they were
incubated with SPIONs–Br–FA. As a result, the SPIONs–Br–FA
displayed higher migration inhibition rates compared to neat
Br in FAR+ cancer cells. The scratch assay ndings suggest that
SPIONs–Br–FA have the ability to inhibit signicantly the
migration of HeLa, MDA-MB-231, and 4T1 cell lines.
The spread of metastatic cancer cells is the reason behind
almost 90% of the cancer deaths in human and is a signicant
barrier in cancer therapy.95,96 Cell migration is one of the most
crucial steps involved in metastasis, which is the most life-
threatening stage of cancer.97 As shown in Fig. 8(a)–(c), the
neat Br and SPIONs–Br–FA inhibited signicantly the migration
of MDA-MB-231, HeLa, and 4T1 cell lines. Cell migration
quantitative analysis results are shown in Fig. S4,† with the
results expressed as a percentage of cell migration aer 24 h. As
a result, cells treated with SPIONs–Br–FA showed better inhi-
bition of cell migration compared to neat Br in FAR+ cancer
cells. It can be suggested that the higher inhibitory eﬀects of
SPIONs–Br–FA on MDA-MB-231, HeLa, and 4T1 cells migrationration after treatment with neat Br and SPIONs–Br–FA. Images were
time intervals (0, 12, and 24 h). (d) Qualitative analysis of the colony-
cer cells.
RSC Adv., 2017, 7, 40074–40094 | 40087
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View Article Onlinewere likely because of its higher cytotoxic eﬀect compared to the
neat Br, which was due to the greater internalization of Br
through the FAR receptors on the surface of FAR+ cancer cells.
As a result, more Br was internalized to the FAR+ cells, which led
to a higher cytotoxicity and consequently a higher number of
cells lost their migration ability and themigration percentage of
FAR+ cancer cells was signicantly decreased. It could thus be
concluded that SPIONs–Br–FA eﬀectively inhibited FAR+ cancer
cells migration compared to the neat Br.
In order to compare the potential of neat Br and SPIONs–Br–
FA for suppressing the growth of FAR+ cell lines, a clonogenic
assay was carried out. For the measurement of clonogenicity,
the cells were exposed to neat Br (at the IC50 concentration) and
SPIONs–Br–FA (at the IC50 concentration of neat Br). As depic-
ted in Fig. 8(d), the ndings revealed a signicant clonogenic
inhibition of all FAR+ cancer cells treated with neat Br and
SPIONs–Br–FA. Non-treated cells (negative control) produced
a large number of colonies compared to treated cells. The size
and number of colonies were signicantly reduced, particularly
for SPIONs–Br–FA treated FAR+ cancer cells. Comparisons
between the colony-forming abilities of neat Br and SPIONs–Br–
FA in FAR+ cancer cells indicated that the SPIONs–Br–FA had
a higher colony-forming-inhibitory eﬀect compared to neat Br.
It was clearly evident that SPIONs–Br–FA exerted a suppressing
eﬀect on the colony formation of FAR+ cancer cells. The reason
for this could be due to the higher internalization of Br through
the FAR receptors on the surface of FAR+ cancer cells, which ledFig. 9 (a) Tumor volume after treatment (group 1), (*) indicates signiﬁ
followed by the Holm–Sidak post hoc test (p < 0.05). (b) Survival rate% afte
0.05) and (**P < 0.01) indicate signiﬁcant diﬀerences compared to the con
(group 2). (e) Image of mice bearing the 4T1 breast tumor in situ and a
staining and observed under a microscope (100).
40088 | RSC Adv., 2017, 7, 40074–40094to a greater internalization of Br to the FAR+ cells and estab-
lished a higher cytotoxicity and consequently decreased the
survival rate (lower colony-forming ability). It could thus be
concluded that SPIONs–Br–FA eﬀectively decreased the colony-
forming ability of FAR+ cancer cells compared to the neat Br.
Quantitative analysis (Fig. S5†) of the colony-forming-
inhibition potential of both neat Br and SPIONs–Br–FA
against MDA-MB-231, HeLa, and 4T1 cells indicated that the
latter displayed the best ability. Pair-wise comparison of the
SPIONs–Br–FA versus neat Br indicated that Br's eﬀectiveness
was lower at limiting the growth, migration, and colony-
forming abilities of FAR+ cell lines.In vivo anticancer eﬃcacy
The 4T1-tumor-bearingmicemodel was established about 2 to 2
weeks aer the cancer cells induction to the female Balb/C
mice. Fig. 9(e) shows the 4T1 breast tumor in situ, which was
conrmed by histological analysis. The tumor region consisted
of viable tumor cells, which displayed numerous focal areas of
necrosis, suggesting a massive tumor formation.
The most common animal models used in biomedical
research are mice due to 95% of their genes sharing homology
with humans. Observations in this study showed that tumors
began to appear within 2 to 3 weeks aer the initiation of 4T1
cells. 24 h aer 4T1 cells inoculation, the mice were subjected to
the rst treatment (intravenous injection (IV)). The groups (n ¼
6) were as follows: saline, SPIONs–COOH (10 mg kg1), neat Brcant diﬀerence compared to the control analyzed by unpaired t-test
r treatment (group 1). (c) Tumor volume after treatment (group 2), (*P <
trol analyzed by one-way ANOVA. (d) Extracted tumors after treatment
histological slice of tumor. The tumor section was stained using H&E
This journal is © The Royal Society of Chemistry 2017
Fig. 10 Quantitative biodistribution study (AAS method). (*) indicates
a signiﬁcant diﬀerence compared to the control as analyzed by
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View Article Online(10 mg kg1), SPIONs–Br (10 mg kg1), SPIONs–Br (8 mg kg1),
and SPIONs–Br (4 mg kg1). As shown in Fig. 9(a), the tumor
growth rate of the saline- and SPIONs–COOH-injected groups
was signicantly higher than the other groups treated with neat
Br and SPIONs–Br at diﬀerent concentrations, and the survival
period of the 4T1-tumor-bearing mice model, which was
observed for 60 days aer tumor implantation showed that
SPIONs–Br (at a concentration of 8 mg kg1) prolonged the
lifespan of the mouse model (Fig. 9(b)) compared to SPIONs–Br
(at a concentration of 10 mg kg1) and neat Br (at a concentra-
tion of 10 mg kg1). These results demonstrated that the
treatment of the 4T1-bearing mice model with SPIONs–Br (8 mg
kg1) signicantly inhibited tumor growth and improved the
survival rate. Therefore, the concentration of 8 mg kg1 was
chosen to be used for the experiments in the second group.
The second group of experiments was designed to nd out
the tumor inhibition eﬀect at this concentration for diﬀerent
nanoparticles formulation and to explore the FA targeting
function in a living model. The second groups (n ¼ 6) of
experiments were injected intravenously by saline, SPIONs–FA
(8 mg kg1), neat Br (1 mg kg1), SPIONs–Br (8 mg kg1–1 mg
kg1 Br concentration), SPIONs–Br–FA (8 mg kg1–1 mg kg1 Br
concentration), and SPIONs–Br–FA (8 mg kg1–1 mg kg1 Br
concentration) + the coinjection of excess FA (1 mM free folic
acid). The amounts of Br administered were 1 mg kg1 in all of
the formulations.
As shown in Fig. 9(c), the tumor volume measurements 60
days aer treatment for the second group with diﬀerent
formulations (at a concentration of 8 mg kg1) demonstrated
that the mice treated with SPIONs–Br–FA had an appreciably
smaller tumor than the other treatment groups. To be more
specic, the live models were sacriced and the tumors were
then extracted and subjected to size measurement.
The photographs of the tumors illustrated that the smallest
tumor belonged to the live models injected with SPIONs–Br–FA,
followed by the live models injected with SPIONs–Br and neat Br
(Fig. 9(d)). During the period of this experiment (60 days), all of
the live models were alive. The tumor volumes of each group
changed diﬀerently, owing to the targeting eﬀect of SPIONs–Br–
FA to the tumor site, whereby more Br reached the tumor site,
which led to better results. The ability of the higher targeting
eﬃciency to the tumor by SPIONs–Br–FA was striking and
directly responsible for the higher tumor suppression eﬃcacy
than for the other formulations in the treatment groups.
These results are in agreement with the study carried out by
ref. 66, which demonstrated that the targeted delivery of
methotrexate (anticancer agent) increased its anti-tumor
activity and markedly decreased its toxicity which is not
possible with a neat and non-targeting methotrexate. In 2014,98
a study showed that bromelain's anticancer activity could be
signicantly boosted and the lifespan of bromelain-treated
tumor-bearing mice could be remarkably extended when
bromelain was encapsulated into poly(lactic-co-glycolic acid) in
comparison to neat bromelain. It is satisfactory to draw
a conclusion in this study that SPIONs–Br–FA successfully
targets and nds its way into the tumor cells through FAR+This journal is © The Royal Society of Chemistry 2017receptors, which thus aﬀords a promising treatment, while toxic
side eﬀects remarkably declined.Biodistribution study
To understand the biodistribution and in vivo targeting eﬃcacy of
the functionalized nanoparticles, the biodistribution of SPIONs–
COOH and SPIONs–FA in diﬀerent major organs as well as in
tumors, the 4T1-bearing mice model were sacriced at 4, 12, and
24 h aer intravenous administration. The biodistribution was
expressed as the percentage of injected dose per gram of each
organ (% ID per g). The animals were sacriced and dissected 4,
12, and 24 h aer injection. The live models in the control group
were injected with PBS. Noteworthy quantitative and qualitative
diﬀerences in the samples biodistribution was seen, s can be seen
in Fig. 10 and S6,† respectively. Both SPIONs–COOH and SPIONs–
FA taken up by the liver and spleen (parts of the reticuloendo-
thelial system (RES)) may reduce the unpredictable side eﬀects for
eﬀective long-term treatment.99 However, the accumulation of
SPIONs–FA in the liver was higher than SPIONs–COOH, which
may be due to the increment in the size and diﬀerent surface
characteristics of the SPIONs–FA.
These results revealed the specic localization of SPIONs–FA
at the site of the tumor. Importantly, SPIONs–FA could increase
the iron concentration in the tumor compared to SPIONs–
COOH (P < 0.05). The iron concentration increase at the tumor
site was by a factor of 1.9-fold at 4 h aer injection, 2.1-fold at
12 h aer injection, and 2.6-fold higher at 24 h aer injection, as
shown in Fig. 10. An increment in the blood iron concentration
was seen 4 h post-injection of SPIONs–FA; however, it was
lowered in the next 24 h. For the passive targeting group,
SPIONs–COOH were observed to be accumulated at the tumor
sites, indicating SPIONs–COOH could preferentially accumu-
late in the tumor tissues due to the EPR (enhanced permeabilityunpaired t-test followed by a Holm–Sidak post hoc test (p < 0.05).
RSC Adv., 2017, 7, 40074–40094 | 40089
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View Article Onlineand retention) eﬀects (Fig. 10 and S6†). In the absence of folate
targeting, the EPR eﬀect of SPIONs is the major mechanism of
uptake.99 However, the amount of SPIONs–COOH at the tumor
locations was less than for active SPIONs–FA (p < 0.05), which
fully suggests that the prepared SPIONs–FA has the ability to
target tumor tissues.
Experiments with co-injected FA resulted in a nearly
complete blockade in the kidneys and tumor tissue showing the
FAR+ specic uptake of SPIONs–FA in these tissues and organs.
Generally, there is a critical aspect with the FAR targeting
strategy that is related to SPIONs–FA high retention in the
kidneys. In the primary urine, FARs are exposed to a high folate
conjugate concentration due to the fact that the expression of
the FARs happens on the luminal side of the brush border
membrane.99,100 As a consequence, folate is signicantly and
specically accumulated in the renal tissues. As shown in
Fig. 10, a high number of SPIONs–FA are accumulated in the
kidneys. The high binding and uptake of SPIONs–FA into the
renal tissue is a logical consequence of FAR expression in the
proximal tubule cells, which causes the high uptake and
binding of SPIONs–FA in the kidneys, which is an unwanted
side eﬀect in the development of SPIONs–FA for therapeutic
purposes.100 To conclude, the biodistribution results illustrated
that SPIONs–FA could be an ideal targeting candidate for the
FAR+ metastatic cancers in biomedical applications.
4. Conclusion
In summary, bromelain was successfully conjugated to the
folate-targeted superparamagnetic g-Fe2O3 nanoparticles,
which were coated with citric acid via a method of direct addi-
tion. A novel SPIONs–Br–FA complex was successfully synthe-
sized, then characterized physicochemically (FT-IR, AAS, DLS,
VSM, XRD, TGA, TEM, and FESEM), and tested for in vitro and in
vivo tumor-targeting characteristics. A higher transport of
SPIONs–FA through the mechanism of the receptor endocytosis
pathway into FAR+ cells (HeLa, MDA-MB-231, and 4T1) resulted
in a high accumulation of SPIONs–FA in them compared to
FAR cell lines (HSF 1184 and MDA-MB-468), which was
assured to occur via qualitative and quantitative in vitro binding
studies (Prussian blue assay and AAS analysis). Qualitative and
quantitative biodistribution studies (AAS analysis and TEM
staining method) clearly revealed the targeting of SPIONs–FA to
the tumor site. The nal engineered SPIONs–FA possessed
desirable characteristics, adequate size, and long-term dis-
persibility, and could remain stable in solutions with satisfying
cells and blood biocompatibility, which made it a quite exqui-
site and reliable choice to play a noticeable role as a drug-
delivery carrier in cancer therapy. In vitro (MTT assay) and in
vivo (4T1-bearing Balc/C mice model) cytotoxicity studies
showed a signicant dose advantage with SPIONs–Br–FA in
reducing the IC50 values compared with neat Br. Additionally,
SPIONs–Br–FA was a rewarding candidate to suppress cell
growth and could make an enormous morphological alterna-
tion in treated cells compared to neat Br. Furthermore, the
colony formation and migration capabilities of the cells treated
SPIONs–Br–FA were signicantly prohibited compared to the40090 | RSC Adv., 2017, 7, 40074–40094neat Br-treated cells. In the cells treated with SPIONs–Br–FA,
more signs of apoptosis and a lower number of live cells were
observed compared to the cells treated with neat Br. In other
word, SPIONs–Br–FA induced a higher percentage of apoptotic
cells than the neat Br. Excellent biocompatibility of the SPIONs–
FA and therapeutic eﬃcacy of the SPIONs–Br–FA in FAR+ cancer
cells in vitro and in vivo were demonstrated. An improved in vivo
cytotoxic eﬀect was obtained for SPIONs–Br–FA in comparison
with SPIONs–Br and neat Br, respectively. The ability of a higher
targeting eﬃciency of SPIONs–Br–FA to the tumor site in the
4T1-bearing Balc/C mice model may have been responsible for
the higher tumor inhibition eﬃcacy than with the other SPIONs
formulations in the treatment groups. Herein this study, it was
conveyed that dual-functional synthesized SPIONs–Br–FA is
a great candidate to inhibit the tumor growth in a live model
with no damage to normal tissues. Considering the unique and
favorable properties of SPIONs–Br–FA, the formulation can be
fruitfully exploited to improve the deliverability of poor bio-
available drugs and may open up certain avenues in cancer
therapy and thus act as an attractive and promising treatment
option for patients.
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